2025
Cenobamate and pregnancy: A-single level 4 epilepsy center experience
Jimenez A, Toghramadjian I, Okafor C, Hanin A, Zhou X, Dorotan M, Nuthalapati P, Sakya S, Hirsch L, Altalib H, Lazorwitz A, Herlopian A. Cenobamate and pregnancy: A-single level 4 epilepsy center experience. Epilepsy & Behavior 2025, 169: 110440. PMID: 40318387, DOI: 10.1016/j.yebeh.2025.110440.Peer-Reviewed Original ResearchConceptsConcentration-to-dose ratioPost-partum periodUnintended pregnancyContraceptive methodsSingle-center retrospective chart reviewFemales of childbearing ageEarly-term birthPrevent unintended pregnancyAdult female patientsDrug level monitoringMonths of agePre-conceptual counsellingElective terminationSpontaneous miscarriagePregnancy outcomesCongenital malformationsFemale patientsHormonal contraceptionChildbearing ageMedical comorbiditiesCenobamatePregnancyContraceptive usePharmacokinetic profilePatientsSerum anti-mullerian hormone levels and age among Samoan women
O’Brien G, Lambert-Messerlian G, Hawley N, Fidow U, Naseri T, Reupena M, Kershaw E, Azar M, Pangburn M, McGarvey S. Serum anti-mullerian hormone levels and age among Samoan women. Reproductive Biology And Endocrinology 2025, 23: 45. PMID: 40108611, PMCID: PMC11921511, DOI: 10.1186/s12958-025-01379-y.Peer-Reviewed Original ResearchConceptsPCOS prevalencePolycystic ovary syndromeSerum anti-Mullerian hormoneAnti-Mullerian hormoneAnti-Mullerian hormone levelsSamoan womenAssociation of anti-Mullerian hormoneContraceptive useBody mass indexSerum anti-mullerian hormone levelsEthnic minority populationsHormonal contraceptive useAMH levelsAssociated with ageFree androgen indexMinority populationsSex hormone binding globulinReproductive healthAssociated with body mass indexSerum total testosteroneAndrogen indexPrevalence of obesityRelated declineTobacco useAdult womenThe 2024 US Medical Eligibility Criteria for Contraceptive Use: Application to Practice in the Care of Patients With Cardiac Disease
Shapero K, Madden T. The 2024 US Medical Eligibility Criteria for Contraceptive Use: Application to Practice in the Care of Patients With Cardiac Disease. Circulation Research 2025, 136: 566-582. PMID: 40080533, DOI: 10.1161/circresaha.125.325682.Peer-Reviewed Original ResearchConceptsCardiac disease statesCardiac diseaseIntrauterine deviceMedical Eligibility Criteria for Contraceptive UseContraceptive methodsUS Medical Eligibility CriteriaContraceptive useEffective reversible contraceptive methodsProgestin-only methodsMedical Eligibility CriteriaAssociated with increased riskReversible contraceptive methodsAcquired heart diseaseUS Centers for Disease Control and PreventionDisease statesCenters for Disease Control and PreventionDisease Control and PreventionContraceptive counselingControl and PreventionMaternal mortalityCare of patientsUnplanned pregnancyEligibility criteriaPatientsHeart disease
2024
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2
Phillips K, Kotsopoulos J, Domchek S, Terry M, Chamberlain J, Bassett J, Aeilts A, Andrulis I, Buys S, Cui W, Daly M, Eisen A, Foulkes W, Friedlander M, Gronwald J, Hopper J, John E, Karlan B, Kim R, Kurian A, Lubinski J, Metcalfe K, Nathanson K, Singer C, Southey M, Symecko H, Tung N, Narod S, Milne R, the Risk Factor Analysis of Hereditary Breast and Ovarian Cancer Study T, Study T, Amor D, Andrews L, Antill Y, Balleine R, Beesley J, Bennett I, Bogwitz M, Bodek S, Botes L, Brennan M, Brown M, Buckley M, Burke J, Butow P, Caldon L, Campbell I, Cao M, Chakrabarti A, Chauhan D, Chauhan M, Chenevix-Trench G, Christian A, Cohen P, Colley A, Crook A, Cui J, Courtney E, Cummings M, Dawson S, DeFazio A, Delatycki M, Dickson R, Dixon J, Edwards S, Farshid G, Fellows A, Fenton G, Field M, Flanagan J, Fong P, Forrest L, Fox S, French J, Friedlander M, Gaff C, Gattas M, George P, Greening S, Harris M, Hart S, Harraka P, Hayward N, Hopper J, Hoskins C, Hunt C, James P, Jenkins M, Kidd A, Kirk J, Koehler J, Kollias J, Lakhani S, Lawrence M, Lee J, Li S, Lindeman G, Lippey J, Lipton L, Lobb L, Loi S, Mann G, Marsh D, McLachlan S, Meiser B, Milne R, Nightingale S, O'Connell S, O'Sullivan S, Ortega D, Pachter N, Pang J, Pathak G, Patterson B, Pearn A, Phillips K, Pieper E, Ramus S, Rickard E, Ragunathan A, Robinson B, Saleh M, Skandarajah A, Salisbury E, Saunders C, Saunus J, Savas P, Scott R, Scott C, Sexton A, Shaw J, Shelling A, Srinivasa S, Simpson P, Southey M, Spurdle A, Taylor J, Taylor R, Thorne H, Trainer A, Tucker K, Visvader J, Walker L, Williams R, Winship I, Young M, Zaheed M. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2. Journal Of Clinical Oncology 2024, 43: 422-431. PMID: 39356978, PMCID: PMC11771360, DOI: 10.1200/jco.24.00176.Peer-Reviewed Original ResearchAssociated with increased BC riskBC riskHormonal contraceptionMutation carriersBreast cancerAssociated with BC riskCarriers of germline mutationsBreast cancer riskMedian Follow-UpAssociated with increased riskIncreased breast cancerHormonal contraceptive useProspective cohort studyGermline mutationsFollow-upCohort studyCox regressionCancer riskContraceptive useContraceptionCumulative durationMutationsRiskProportional increaseYearsDoes reversible postpartum contraception reduce the risk of pregnancy condition recurrence? A longitudinal claims-based study from Maine
Ahrens K, Palmsten K, Lipkind H, Ackerman-Banks C, Grantham C. Does reversible postpartum contraception reduce the risk of pregnancy condition recurrence? A longitudinal claims-based study from Maine. Annals Of Epidemiology 2024, 96: 58-65. PMID: 38885800, PMCID: PMC11283344, DOI: 10.1016/j.annepidem.2024.06.001.Peer-Reviewed Original ResearchDays of deliveryPostpartum contraceptive useInterpregnancy intervalPregnancy conditionsReversible contraceptionPrenatal depressionRisk of prenatal depressionContraceptive useShort interpregnancy intervalAssociated with recurrenceRisk of recurrenceAssociated with lower riskLog-binomial regression modelsModerately effective methodsEstimate risk ratiosHypertensive disordersIndex pregnancyPostpartum contraceptionPregnancy deliveryClaims-based studyGestational diabetesIntrauterine deviceIntrapartum periodContraceptive initiationPregnancyLetter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’
Kendall P, Lazorwitz A. Letter to the Editor in Response to ‘Population-based cohort study of oral contraceptive use and risk of depression’. Epidemiology And Psychiatric Sciences 2024, 33: e4. PMID: 38299323, PMCID: PMC10894698, DOI: 10.1017/s2045796024000039.Peer-Reviewed Original ResearchCOVID‐19 and Contraceptive Use in Two African Countries: Examining Conflicting Pressures on Women
Yu J, Grace K, Boyle E, Mikal J, Gunther M, Kristiansen D. COVID‐19 and Contraceptive Use in Two African Countries: Examining Conflicting Pressures on Women. Population And Development Review 2024, 50: 395-419. PMID: 39309043, PMCID: PMC11412435, DOI: 10.1111/padr.12606.Peer-Reviewed Original ResearchContraceptive useMultilevel logistic regression resultsLogistic regression resultsReproductive health servicesDelay pregnancyAfrican countriesContraceptive uptakeAccess contraceptionMultilevel perspectiveAbstract WomenContraceptionConflicting pressuresVirus exposureHealth servicesLongitudinal dataInterpersonal trustRegression resultsPublic health crisisBurkina FasoWomenMobility restrictionsCOVID-19COVID-19 precautionsPublic health officialsHealth crisis
2023
Association between serum 25-hydroxyvitamin D and antimüllerian hormone levels in a cohort of African-American women
Subramanian A, Harmon Q, Bernardi L, Carnethon M, Marsh E, Baird D, Jukic A. Association between serum 25-hydroxyvitamin D and antimüllerian hormone levels in a cohort of African-American women. Fertility And Sterility 2023, 121: 642-650. PMID: 38145700, PMCID: PMC10978232, DOI: 10.1016/j.fertnstert.2023.12.023.Peer-Reviewed Original ResearchHigher AMH levelsLower AMH levelsAMH levelsAfrican American womenHigher oddsMAIN OUTCOMELower oddsAntimüllerian hormone levelsSerum AMH levelsPolycystic ovary syndromeHormonal contraceptive useBody mass indexTime of enrollmentCross-sectional studyExclusion of participantsClinical trial designAntimüllerian hormoneOvarian reserveOvary syndromeProspective cohortMass indexPrior diagnosisD levelsHormone levelsContraceptive usePractice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelines
Wang C, Meriggiola M, Amory J, Barratt C, Behre H, Bremner W, Ferlin A, Honig S, Kopa Z, Lo K, Nieschlag E, Page S, Sandlow J, Sitruk‐Ware R, Swerdloff R, Wu F, Goulis D. Practice and development of male contraception: European Academy of Andrology and American Society of Andrology guidelines. Andrology 2023, 12: 1470-1500. PMID: 37727884, DOI: 10.1111/andr.13525.Peer-Reviewed Original ResearchMale contraceptionContraceptive methodsClinical practiceNon-hormonal methodsLack of efficacyUnintended pregnancy ratesEvidence-based recommendationsMale contraceptive methodsAmerican SocietyMale contraceptive developmentAndrology (EAA) guidelinesConsensus guidelinesContraceptive efficacySurgical methodsHormonal methodsPregnancy rateContraceptive useGRADE systemOcclusion methodEuropean AcademySemen analysisReproductive risksContraceptionFamily planningEuropean SocietyInfluence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot study
Taylor H, Alhasan S, Saleem M, Poole S, Jiang F, Longbrake E, Bove R. Influence of menstrual cycle and hormonal contraceptive use on MS symptom fluctuations: A pilot study. Multiple Sclerosis And Related Disorders 2023, 77: 104864. PMID: 37480738, PMCID: PMC11090415, DOI: 10.1016/j.msard.2023.104864.Peer-Reviewed Original ResearchConceptsContinuous oral contraceptivesOral contraceptivesOC usersMenstrual cycleSymptom fluctuationsPilot studyTwo-centre pilot studyRegular menstrual cyclesHormonal contraceptive useIntrauterine device usersMenstrual cycle phaseFuture confirmatory studiesMedian EDSSMean ageGeneralized symptomsHormonal measurementsPerimenstrual periodSymptom SurveyContraceptive useLarge cohortLuteal periodClinical practiceContraceptive choicesParticipant retentionSymptom severityImproving the Health and Readiness of Military Women
Witkop C, Kostas-Polston E, Degutis L. Improving the Health and Readiness of Military Women. Military Medicine 2023, 188: 8-14. PMID: 36882034, DOI: 10.1093/milmed/usac354.Peer-Reviewed Original ResearchConceptsMilitary Health SystemPreventive health servicesUnintended pregnancyContraceptive methodsGeneral populationMilitary womenOptimal healthWomen's preventive health servicesAbnormal uterine bleedingReproductive health issuesMeasures of healthService delivery targetsGynecologic healthUterine bleedingContraceptive utilizationInfant outcomesGynecologic conditionsMenstrual cycleContraceptive optionsContraceptive useMedical conditionsMenstrual suppressionPregnancyHealth servicesContraceptive accessLifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu Z, Brooks M, Irvin S, Jordan S, Aben K, Anton-Culver H, Bandera E, Beckmann M, Berchuck A, Brooks-Wilson A, Chang-Claude J, Cook L, Cramer D, Cushing-Haugen K, Doherty J, Ekici A, Fasching P, Fortner R, Gayther S, Gentry-Maharaj A, Giles G, Goode E, Goodman M, Group A, Harris H, Hein A, Kaaks R, Kiemeney L, Köbel M, Kotsopoulos J, Kotsopoulos J, Le N, Lee A, Matsuo K, McGuire V, McLaughlin J, Menon U, Milne R, Moysich K, Pearce C, Pike M, Qin B, Ramus S, Riggan M, Rothstein J, Schildkraut J, Sieh W, Sutphen R, Terry K, Thompson P, Titus L, van Altena A, White E, Whittemore A, Wu A, Zheng W, Ziogas A, Taylor S, Tang L, Songer T, Wentzensen N, Webb P, Risch H, Modugno F. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. Journal Of The National Cancer Institute 2023, 115: 539-551. PMID: 36688720, PMCID: PMC10165492, DOI: 10.1093/jnci/djad011.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOral contraceptive useClear cell histotypeOvulatory yearsOvulation suppressionOdds ratioOvarian cancerContraceptive useNonmucinous epithelial ovarian cancerConfidence intervalsConsistent protective effectCase patientsMucinous tumorsPooled analysisProtective effectEOC riskControl participantsHistotypeCancerOvulationAssociationRegression modelsRiskYearsBeta coefficientsThe role of combined oral contraceptive use on the serotonin 2A receptor brain architecture in healthy women
Kauffmann A, Larsen S, Ozenne B, Svarer C, Fisher P, Sankar A, Frokjaer V. The role of combined oral contraceptive use on the serotonin 2A receptor brain architecture in healthy women. Neuroscience Applied 2023, 2: 102445. DOI: 10.1016/j.nsa.2023.102445.Peer-Reviewed Original Research
2022
Relationship Between Dating Violence and Contraceptive Use Among Texas Adolescents
Srikanth N, Weerakoon S, Mathew M, Xie L, Messiah S. Relationship Between Dating Violence and Contraceptive Use Among Texas Adolescents. Journal Of Interpersonal Violence 2022, 38: 4852-4876. PMID: 36000420, DOI: 10.1177/08862605221119519.Peer-Reviewed Original ResearchConceptsDating violenceTexas adolescentsContraceptive useUnplanned pregnancyYouth Risk Behavior Surveillance System dataSexual dating violenceSexually transmitted infectionsDating violence preventionImpact reproductive healthLogistic regression analysisNoncontraceptive useAntiabortion lawsHormonal contraceptionViolence preventionSurveillance System dataViolenceCondom useReproductive outcomesMultinomial logistic regression analysisReproductive healthAge groupsLawPregnancyContraceptionRegression analysisConsiderations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age
Hsu FI, Lumry W, Riedl M, Tachdjian R. Considerations in the management of hereditary angioedema due to C1-INH deficiency in women of childbearing age. Allergy, Asthma & Clinical Immunology 2022, 18: 64. PMID: 35831891, PMCID: PMC9281160, DOI: 10.1186/s13223-022-00689-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHereditary angioedemaHealth statusAdverse fetal outcomesCohort of patientsChoice of therapyContinuity of careMedical Advisory BoardC1-INH deficiencyWomen's health statusRisk-benefit assessmentHAE attacksHAE managementFetal outcomesProphylactic therapyPatient populationTreatment optionsFemale sexDisease burdenTreatment decisionsContraceptive useUnpredictable episodesTreatment efficacyMucous membranesGynecologic specialistsPregnancyThe association between hormonal contraceptive use and smoking, negative affect, and cessation attempts in college females
Stewart S, Peltier M, Roys M, Copeland A. The association between hormonal contraceptive use and smoking, negative affect, and cessation attempts in college females. Drug And Alcohol Dependence Reports 2022, 3: 100063. PMID: 36845992, PMCID: PMC9948877, DOI: 10.1016/j.dadr.2022.100063.Peer-Reviewed Original ResearchHormonal contraceptivesHC useCurrent smokingCessation attemptsCombination hormonal contraceptivesHormonal contraceptive useEndogenous female hormonesSmoking status interactionFemale hormonesContraceptive useQuit attemptsLower anxiety levelsNicotine useTreatment targetsPast cessation attemptsSmokingCurrent HC useProgestinsExogenous hormonesAdditional studiesWomenStatus interactionAnxiety levelsSignificant differencesSignificant main effectHepatocellular adenoma: Where are we now?
Wang X, Zhang X. Hepatocellular adenoma: Where are we now? World Journal Of Gastroenterology 2022, 28: 1384-1393. PMID: 35582672, PMCID: PMC9048476, DOI: 10.3748/wjg.v28.i14.1384.Peer-Reviewed Original ResearchConceptsHepatocellular adenomaOral contraceptive useUnderlying molecular signaturesClinical managementHepatocellular neoplasmsContraceptive useHigh riskMalignant transformationYoung womenMolecular featuresMolecular signaturesSubtypesMolecular studiesClassification systemComplicationsHemorrhageAdenomasNeoplasmsOverlapping needs for sexual and reproductive health and HIV prevention in women with substance use disorders
Gibson B, Hoff E, Haas A, Adams ZM, Price CR, Goddard-Eckrich D, Sheth SS, Dasgupta A, Meyer JP. Overlapping needs for sexual and reproductive health and HIV prevention in women with substance use disorders. Women's Health 2022, 18: 17455065211070543. PMID: 35023410, PMCID: PMC8771433, DOI: 10.1177/17455065211070543.Peer-Reviewed Original ResearchConceptsSubstance use disordersPre-exposure prophylaxisUse disordersHIV preventionReproductive healthReproductive health service utilizationHigh HIV risk behaviorHealth service utilizationUnique health issuesCross-sectional evaluationHIV risk behaviorsHigh unmet needReproductive health behaviorsReproductive health needsConcurrent clinical trialsForm of contraceptionTime of assessmentPregnancy intentionReproductive ageClinical trialsUnintended pregnancyService utilizationCriminal justice involvementDrug treatmentContraceptive use
2021
Reducing the Prevalence of Alcohol-Exposed Pregnancies in the United States: A Simulation Modeling Study
Yaesoubi R, Mahin M, Martin G, Paltiel AD, Sharifi M. Reducing the Prevalence of Alcohol-Exposed Pregnancies in the United States: A Simulation Modeling Study. Medical Decision Making 2021, 42: 217-227. PMID: 34166146, PMCID: PMC8702569, DOI: 10.1177/0272989x211023203.Peer-Reviewed Original ResearchConceptsAlcohol-exposed pregnancyUnintended pregnancyPublic health effortsAlcohol abstinenceHealth effortsDifferent public health strategiesPublic health strategiesPrevalence of alcoholFamily Growth dataAwareness of pregnancyReproductive ageEffective contraceptionLive birthsContraceptive useUS womenHealth strategiesPregnancyWoman's riskPrevalenceDrinking patternsSexual activityWomenAbstinenceAlcoholic drinksNational surveyAssociations between Adverse Childhood Experiences and Sexual Risk among Postpartum Women
Thomas JL, Lewis JB, Ickovics JR, Cunningham SD. Associations between Adverse Childhood Experiences and Sexual Risk among Postpartum Women. International Journal Of Environmental Research And Public Health 2021, 18: 3848. PMID: 33917634, PMCID: PMC8038841, DOI: 10.3390/ijerph18073848.Peer-Reviewed Original ResearchConceptsRapid repeat pregnancyACE exposureSexual riskPostpartum womenRepeat pregnancyPostpartum periodContraceptive methodsChild health outcomesYears of ageSexual risk outcomesAdverse childhood experiencesChildhood experiencesRisky sexual behaviorSTI acquisitionMaternal healthEpidemiological evidenceReproductive ageContraceptive useHealth outcomesCondom useAge 18Logistic regressionPregnancyWomenConvenience sample
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply